|
DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Personnel Ad hoc Announcement according to Art. 17 Market Abuse Regulation Resignation of Chairman of the Supervisory Board Venlo, The Netherlands, August 21, 2020 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that Dr. Håkan Björklund, Chairman of the Supervisory Board, has resigned from office as Chairman of the Supervisory Board with immediate effect and has left the Supervisory Board. Dr. Björklund was appointed as member of the Supervisory Board of QIAGEN in March 2017 and served as Chairman since June 2018. Lawrence A. Rosen has been elected by the Supervisory Board as new Chairman of the Supervisory Board. Mr. Rosen has been a member of the Supervisory Board since 2013. QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands ISIN: NL0012169213 Frankfurt Stock Exchange, Regulated Market (Prime Standard) Contacts QIAGEN N.V.: Corporate Communications John Gilardi, Tel: +49 2103 29 11711; john.gilardi@qiagen.com About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
21-Aug-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | QIAGEN N.V. |
| Hulsterweg 82 | |
| 5912 PL Venlo | |
| Netherlands | |
| Phone: | +31 7735566 - 00 |
| Fax: | +31 77 35566-58 |
| E-mail: | qiagen@qiagen.com |
| Internet: | www.qiagen.com |
| ISIN: | NL0012169213 |
| WKN: | A2DKCH |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX |
| EQS News ID: | 1121897 |
| End of Announcement | DGAP News Service |
|
|
1121897 21-Aug-2020 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
